Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Eli Lilly

Main (gene editing) focus: Genetic disorders in the liver and nervous system

Company stage: Commercial

Diseases (gene editing): Liver diseases and diseases of the central nervous system

Genome editing tool: ADAR RNA editing, Arcus Meganuclease

Funding stage: Public (NASDAQ:LLY)

Location: Indianapolis, Indiana, USA



Gene editing partnerships: ProQR Therapeutics, Precision Biosciences

Eli Lilly is a big pharma company with several commercialised medicines in its portfolio. The company's involvment in the genome-editing space comes primarily through its collaboration with Precision Biosciences, where Eli Lilly gets access to the ARCUS meganuclease gene-editing technology to treat genetic diseases of muscle, CNS and liver. Another collaboration in this space is with ProQR Therapeutics, where Eli Lilly gains access to an ADAR-based RNA-editing technology.


HashtagEli Lilly

Company: Eli Lilly
Search CRISPR Medicine